Verve Therapeutics, Inc.

NasdaqGS:VERV Stock Report

Market Cap: US$630.6m

Verve Therapeutics Dividend

Dividend criteria checks 0/6

Verve Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.7%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$2.34
Dividend yield forecast in 3Y0%

Recent dividend updates

No updates

Recent updates

We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate

Jul 12
We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate

Why Verve Therapeutics Deserves A Spot On Your Watchlist

Jun 13

Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

May 14
Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 12
The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause

Apr 03

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Feb 28
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Verve's Proof-Of-Concept Data Doesn't Inspire Confidence

Feb 13

Vectoring In On Verve Therapeutics

Jan 14

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Jun 07
Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Feb 24
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth

Nov 09
We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth

Verve Therapeutics: Cathie Wood Adds To ARKK

Sep 20

Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate

Aug 23

Verve Therapeutics falls postmarket on $200M stock offering

Jul 20

More CRISPR In Human Subjects

Jul 14

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

May 11
Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Verve Therapeutics: Early-Stage Biotech With A Large Market

Apr 16

Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans

Jan 31
Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans

Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing

Aug 24

Verve Therapeutics jumps 75% in its first day of trading

Jun 17

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if VERV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VERV's dividend payments have been increasing.


Dividend Yield vs Market

Verve Therapeutics Dividend Yield vs Market
How does VERV dividend yield compare to the market?
SegmentDividend Yield
Company (VERV)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.4%
Industry Average (Biotechs)2.7%
Analyst forecast in 3 Years (VERV)0%

Notable Dividend: Unable to evaluate VERV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VERV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate VERV's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as VERV has not reported any payouts.


Discover strong dividend paying companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.